Halberd

Halberd Corporation (OTC: HALB) is a publicly traded, pre-revenue biotechnology company founded in 2018 with a mission to develop novel 'subtractive' therapies for hard-to-treat diseases. Its core strategy leverages patented extracorporeal filtration technologies, licensed from Marv Enterprises, to remove causative agents like viruses, toxins, and misfolded proteins from bodily fluids. Recent achievements include initiating research collaborations with Arizona State University and Mississippi State University, and the 2025 acquisition of NeuroSense AI Corp. to augment its neuroscience assessment capabilities. The company maintains an ambitious, wide-ranging pipeline spanning COVID-19, sepsis, cancer, PTSD, and CTE, though all programs remain in pre-clinical discovery and development.

Patented Sequential Dialysis Technique for the extracorporeal removal of disease-causing agents (e.g., viruses, toxins, misfolded proteins) from blood and cerebrospinal fluid using a subtractive therapy approach.